ERBB2 and neoplasm: Notably, in the current study, HER2 IHC2+/FISH− patients responded similarly to IHC2+/FISH+ and IHC3+ patients, with 72.7%, 60.0%, and 52.6% patients obtained tumor shrinkage, respectively.